James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $572.94, for a total value of $5,729,400.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,814,815.44. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

James Edgemond also recently made the following trade(s):

• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total value of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total value of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56.

United Therapeutics Stock Down 1.5%

Shares of UTHR stock opened at $562.09 on Friday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The firm has a market cap of $23.86 billion, a PE ratio of 20.75, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60. The stock has a 50 day moving average of $565.98 and a 200-day moving average of $515.55.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the firm earned $6.63 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research reports. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada lowered their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics said it will present at the Jefferies Global Healthcare Conference, keeping the company visible to investors and highlighting ongoing engagement with the healthcare investing community. Article Title
• Positive Sentiment: The company also shared updates on its PHINDER screening study and its xenokidney/EXTEND trial, which could support the long-term growth story if the clinical programs continue to progress. Article Title Article Title
• Neutral Sentiment: The stock remains supported by a generally constructive analyst backdrop, with several firms maintaining buy or outperform ratings and some raising price targets, which can help offset near-term concerns.
• Neutral Sentiment: Short-interest data showed no meaningful change in available reported shares, so this does not appear to be a major trading catalyst.
• Negative Sentiment: CEO Martine Rothblatt sold additional United Therapeutics shares, following another recent sale, and CFO James Edgemond also sold stock. Multiple insider sales can weigh on investor sentiment, especially after the company’s recent earnings miss. Article Title Article Title
• Negative Sentiment: United Therapeutics recently reported quarterly EPS and revenue below expectations, which remains an overhang on the shares despite the company’s strong profitability.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of UTHR. Arjuna Capital increased its holdings in United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares in the last quarter. Clearstead Advisors LLC grew its holdings in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 23 shares in the last quarter. Sage Rhino Capital LLC grew its holdings in shares of United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after acquiring an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC grew its holdings in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares in the last quarter. Finally, Meeder Advisory Services Inc. grew its holdings in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 26 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.